Alto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 19, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Alto Neuroscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 during its IPO and subsequent clinical trials [3][4][5]. Company Overview - Alto Neuroscience operates as a clinical-stage biopharmaceutical company [3]. - The company conducted its IPO on February 2, 2024, issuing over 8 million shares at $16.00 per share, raising over $119 million [3]. Product Pipeline - The product pipeline includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of the IPO [3]. Allegations of Misleading Information - The lawsuit claims that the company made false or misleading statements about ALTO-100's effectiveness in treating MDD, overstating its clinical, regulatory, and commercial prospects [4]. - It is alleged that these misrepresentations led to an overestimation of Alto Neuroscience's overall business and financial prospects [4]. Impact of Clinical Trial Results - On October 22, 2024, the company announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a nearly 70% drop in stock price [5]. - Following this announcement, Alto Neuroscience's stock continued to trade below the IPO price of $16.00 per share [6].